Paxlovid, evidence base?

Paxlovid, it this an evidence based intervention in May 2022?Uploaded 04-05-22Paper FDA EMU was based onhttps://www.nejm.org/doi/full/10.1056/NEJMoa2118542EPIC-HR (Evaluation of Protease Inhibition for COVID-19 in High-Risk Patients)1120 patients received nirmatrelvir plus ritonavir1126 received placeboRelative risk reductionRisk of progression to severe Covid-19, 89% lower than the risk with placeboAbsolute risk reductionhttps://www.precisionvaccinations.com/what-paxlovids-absolute-and-relative-covid-19-risk-reduction7% down to 1%symptomatic, unvaccinated, non hospitalized adultsat high risk for progression to severe coronavirus disease 2019July 16 and December 9, 2021If vaccinated people and previously infected people are partly protectedMore people would need to be treated to prevent one adverse eventPfizer press release (5th November 2021)https://www.pfizer.com/news/press-release/press-release-detail/pfizers-novel-covid-19-oral-antiviral-treatment-candidateour oral antiviral candidate, … has the potential to save patients’ lives, reduce the severity of COVID-19 infections, and eliminate up to nine out of ten hospitalizationsPfizer Shares In Vitro Efficacy of Novel COVID-19 Oral Treatment Against Omicron Varianthttps://www.pfizer.com/news/press-release/press-release-detail/pfizer-shares-vitro-efficacy-novel-covid-19-oral-treatmenthttps://www.yalemedicine.org/news/12-things-to-know-paxlovid-covid-19https://www.fda.gov/media/155051/downloadThe results showed in all cases that nirmatrelvir was a potent inhibitor of its target.PAXLOVID™ for Post-Exposure Prophylactic Usehttps://www.pfizer.com/news/press-release/press-release-detail/pfizer-shares-top-line-results-phase-23-epic-pep-studyEvaluated data from 2,957 adultsPfizer observed risk reductions of 32% (5 day course)37% reduction (10 day course)These results, however, were not statistically significant and, as such, the primary endpoint of reducing the risk of confirmed and symptomatic COVID-19 infection in adults who had been exposed to the virus through a household contact was not met.FACT SHEET FOR PATIENTS, PARENTS, AND CAREGIVERS EMERGENCY USE AUTHORIZATION (EUA) OF PAXLOVID FOR CORONAVIRUS DISEASE 2019 (COVID-19) https://www.fda.gov/media/155051/downloadPAXLOVID is not an FDA-approved medicine in the United States. PAXLOVID is an investigational medicine Some medicines may interact with PAXLOVID and may cause serious side effects. If you take too much PAXLOVID, call your healthcare provider or go to the nearest hospital emergency room right away. Possible side effects of PAXLOVID are:Allergic Reactionstrouble swallowing or breathing, swelling of the mouth, lips, or face, throat tightness, hoarseness, skin rashLiver Problems. Tell your healthcare provider right away, loss of appetite, yellowing of your skin and the whites of eyes (jaundice), dark-colored urine, pale colored stools and itchy skin, stomach area (abdominal) pain. Other possible side effects include: altered sense of taste, diarrhea, high blood pressure, muscle aches Dr. Ashish K. Jha, White House, Covid-19 coordinatorThe new White House Covid czar says avoiding all virus infections isn’t the goal of U.S. pandemic policy.Paxlovid, push to reach the vulnerableDoctors are too hesitant to prescribe the drughttps://en.wikipedia.org/wiki/Ashish_JhaSenior Advisor at Albright Stonebridge Grouphttps://www.politico.com/newsletters/transition-playbook/2021/03/23/the-blob-abides-492214The firm advises clients on international policy and global markets Patrick VallanceFrom 2012 to 2018, he was President of Research and Development at global pharmaceutical company, GlaxoSmithKline (GSK) https://www.telegraph.co.uk/news/2020/09/23/revealed-sir-patrick-vallance-has-600000-shareholding-firm-contracted/Cashed £ Learn more about your ad choices. Visit megaphone.fm/adchoices